JP2016128441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128441A5 JP2016128441A5 JP2016001684A JP2016001684A JP2016128441A5 JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5 JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antagonist antibody
- binding portion
- madcam antagonist
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101877P | 2015-01-09 | 2015-01-09 | |
| US62/101,877 | 2015-01-09 | ||
| US201562263197P | 2015-12-04 | 2015-12-04 | |
| US62/263,197 | 2015-12-04 | ||
| US201562263910P | 2015-12-07 | 2015-12-07 | |
| US62/263,910 | 2015-12-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Division JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128441A JP2016128441A (ja) | 2016-07-14 |
| JP2016128441A5 true JP2016128441A5 (enExample) | 2019-08-29 |
| JP6779621B2 JP6779621B2 (ja) | 2020-11-04 |
Family
ID=55275128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016001684A Active JP6779621B2 (ja) | 2015-01-09 | 2016-01-07 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10851163B2 (enExample) |
| EP (2) | EP3242684B1 (enExample) |
| JP (2) | JP6779621B2 (enExample) |
| KR (1) | KR102756784B1 (enExample) |
| CN (3) | CN114377125A (enExample) |
| AU (2) | AU2016205852B2 (enExample) |
| BR (1) | BR112017014793A2 (enExample) |
| CA (1) | CA2916283C (enExample) |
| CL (1) | CL2017001756A1 (enExample) |
| EA (1) | EA037288B1 (enExample) |
| ES (1) | ES2927958T3 (enExample) |
| IL (1) | IL253247B (enExample) |
| MA (1) | MA41314A (enExample) |
| MX (1) | MX385589B (enExample) |
| SG (1) | SG11201705604WA (enExample) |
| WO (1) | WO2016110806A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6904905B2 (ja) * | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR102787394B1 (ko) | 2017-07-14 | 2025-03-26 | 화이자 인크. | MAdCAM에 대한 항체 |
| CN108118093A (zh) * | 2018-03-06 | 2018-06-05 | 谢琳 | Linc00426在制备骨肉瘤转移诊断产品中的用途 |
| US20210030868A1 (en) * | 2019-07-29 | 2021-02-04 | Cai Gu Huang | Formulation of antibody based drugs for treating lung cancer by inhalation |
| CN114164211B (zh) * | 2021-09-16 | 2024-02-27 | 中国人民解放军海军军医大学 | lncRNA及其在肿瘤诊断、治疗和预后判断中的应用 |
| CN113789328A (zh) * | 2021-09-16 | 2021-12-14 | 中国人民解放军海军军医大学 | lncRNA及其在免疫调控及免疫相关疾病诊治中的应用 |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| JP2025538586A (ja) * | 2022-11-22 | 2025-11-28 | 武田薬品工業株式会社 | 非アルコール性脂肪性肝炎の治療のためのＭＡｄＣＡＭ－１抗体の投薬レジメン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US20070202097A1 (en) * | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
| DOP2005000002A (es) * | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| US20100119517A1 (en) | 2005-07-08 | 2010-05-13 | Pfizer Inc | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue |
| PE20070374A1 (es) | 2005-07-08 | 2007-05-12 | Pfizer Ltd | ANTICUERPOS ANTI-MAdCAM |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| DE102010013830A1 (de) * | 2010-03-26 | 2011-09-29 | Carl Zeiss Microlmaging Gmbh | Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe |
| JP6615745B2 (ja) * | 2013-03-27 | 2019-12-04 | ジェネンテック， インコーポレイテッド | ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
-
2015
- 2015-12-23 CA CA2916283A patent/CA2916283C/en active Active
-
2016
- 2016-01-05 MA MA041314A patent/MA41314A/fr unknown
- 2016-01-06 EP EP16702586.5A patent/EP3242684B1/en active Active
- 2016-01-06 CN CN202111331776.8A patent/CN114377125A/zh active Pending
- 2016-01-06 ES ES16702586T patent/ES2927958T3/es active Active
- 2016-01-06 AU AU2016205852A patent/AU2016205852B2/en active Active
- 2016-01-06 KR KR1020177021819A patent/KR102756784B1/ko active Active
- 2016-01-06 BR BR112017014793A patent/BR112017014793A2/pt not_active Application Discontinuation
- 2016-01-06 MX MX2017009047A patent/MX385589B/es unknown
- 2016-01-06 EP EP22179107.2A patent/EP4112079A1/en active Pending
- 2016-01-06 CN CN201680014443.3A patent/CN107427576A/zh active Pending
- 2016-01-06 CN CN202111331779.1A patent/CN114732899A/zh active Pending
- 2016-01-06 WO PCT/IB2016/050047 patent/WO2016110806A2/en not_active Ceased
- 2016-01-06 US US15/542,110 patent/US10851163B2/en active Active
- 2016-01-06 EA EA201791227A patent/EA037288B1/ru unknown
- 2016-01-06 SG SG11201705604WA patent/SG11201705604WA/en unknown
- 2016-01-07 JP JP2016001684A patent/JP6779621B2/ja active Active
-
2017
- 2017-06-29 IL IL253247A patent/IL253247B/en unknown
- 2017-07-03 CL CL2017001756A patent/CL2017001756A1/es unknown
-
2020
- 2020-10-14 JP JP2020173121A patent/JP7142200B2/ja active Active
- 2020-11-30 US US17/107,228 patent/US11884726B2/en active Active
-
2021
- 2021-10-12 AU AU2021250850A patent/AU2021250850B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11180565B2 (en) | Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease | |
| JP7177868B2 (ja) | 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法 | |
| Colman et al. | Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease | |
| JP2023002583A (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| Kneepkens et al. | Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up | |
| Lal et al. | Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment | |
| FI3536710T3 (fi) | Anti-il-36r -vasta-aineita | |
| JP2015504430A (ja) | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 | |
| Eng et al. | Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study | |
| Milman et al. | Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis | |
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| RU2014106658A (ru) | Новое антитело к cxcr4 и его применение для выявления и диагностики рака | |
| Van Stappen et al. | Validation of a sample pretreatment protocol to convert a drug‐sensitive into a drug‐tolerant anti‐infliximab antibody immunoassay | |
| Balandraud et al. | Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis-A three years retrospective study | |
| JP2018504584A (ja) | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 | |
| JP2019508370A (ja) | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ | |
| US20250208140A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| US20240118278A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| Berger et al. | Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study | |
| Martínez-Feito et al. | Optimal concentration range of golimumab in patients with axial spondyloarthritis | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Song et al. | Population pharmacokinetic model for the use of intravenous or subcutaneous infliximab in patients with inflammatory bowel disease: real-world data from a prospective cohort study | |
| Wang et al. | The relationship between hepatitis B virus serum DNA, RNA and quantitative hepatitis B surface antigen, and the predictive value for mother‐to‐child transmission: an observational cohort study | |
| Eder et al. | Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies | |
| Li et al. | A Risk Prediction Model for the Development of Rheumatoid Arthritis, Sjögren's Syndrome, Systemic Sclerosis in Patients With Systemic Lupus Erythematosus: Multicenter Approaches |